Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by francois21on Oct 11, 2015 11:08am
458 Views
Post# 24183288

RE:Therapure Biopharma...

RE:Therapure Biopharma...

Hi duckdog,

Therapure isn't something new around the corner. as it's was formed on the Hemososl ashes years ago. 


As you mentionned, the technology used was acquiered by a danish company.

However, the same technology was acquired by Cangene in 2009, (see my link below) and obviously, Cangene just wasn't able to make money out of it, as they let go the rights after. 

So far, Therapure mentionned a list of proteins that are used as therapeutic. However, they are not showing they can effectivly extract those proteins, and how much. 

Therapure is looking for partnership, but  for now, except a few CMO contracts, they didn't show a lot of things in proteins extraction.

So, can they be in competition with PLI, not really for the moment. A part being a CMO, they seems far away of doing what PLI is doing, which is extract on a commercial scale proteins, and turn them into therapeutic. 

I really think they at least 10-15 years behind Prometic in term of development. Maybe one day, we will see them in a clinical trial for a plasma protein prduct. But by then, PLI will be very well positionned on the market. 

For me, there's nothing to worried about.....

And good news, the government invested money in that company. Have you ever seen a governement investment that went good? :-)  


https://www.nbgipe.com/ventures/news/news-article/items/upfront-chromatography-licenses-use-of-eba-technology-to-cangene/


Bullboard Posts